Mirum Pharmaceuticals VISTAS Study Results for Volixibat in Primary Sclerosing Cholangitis Due May 4, 2026

Key Takeaways

• Mirum Pharmaceuticals will host an investor call on May 4, 2026 at 8:30 a.m. ET to share VISTAS study results
• The study evaluates volixibat as a potential treatment for primary sclerosing cholangitis, a rare liver disease
• Results could impact treatment options for PSC patients who currently have limited therapeutic choices

---

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced it will host an investor call on Monday, May 4, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the VISTAS study evaluating volixibat in patients with primary sclerosing cholangitis (PSC).

About the VISTAS Study

The VISTAS study represents a significant clinical trial for Mirum Pharmaceuticals, focusing on volixibat’s potential as a treatment for primary sclerosing cholangitis. PSC is a rare, chronic liver disease characterized by inflammation and scarring of bile ducts, which can lead to liver failure and the need for transplantation.

Market Impact and Patient Implications

Primary sclerosing cholangitis affects approximately 1-2 people per 100,000 globally, with limited treatment options currently available. The condition primarily impacts men and is often associated with inflammatory bowel disease. Current management focuses on symptom relief and monitoring disease progression, making new therapeutic options critically important for patients.

Volixibat is an investigational ileal bile acid transporter (IBAT) inhibitor that works by blocking bile acid reabsorption in the intestine. This mechanism could potentially reduce bile acid accumulation in the liver, addressing one of the key pathological processes in PSC.

Company Background

Mirum Pharmaceuticals specializes in developing treatments for rare liver diseases. The Foster City, California-based company has built its portfolio around addressing unmet medical needs in hepatology, with volixibat representing a key asset in their pipeline.

The upcoming results announcement will provide crucial data on volixibat’s efficacy and safety profile in PSC patients, potentially influencing the drug’s regulatory pathway and commercial prospects. Given the limited treatment landscape for PSC, positive results could position volixibat as an important therapeutic option for patients and healthcare providers.

Investors and healthcare professionals will be closely monitoring the May 4th call for insights into volixibat’s clinical performance and its potential impact on the rare disease treatment market.

---

Frequently Asked Questions

What is primary sclerosing cholangitis and how common is it?

Primary sclerosing cholangitis (PSC) is a rare chronic liver disease affecting bile ducts, with an incidence of 1-2 per 100,000 people globally. It causes inflammation and scarring that can lead to liver failure.

When will volixibat be available for PSC patients?

Volixibat is still in clinical trials. The May 4, 2026 results will determine next steps, but regulatory approval and commercial availability would require additional time and successful trial outcomes.

How does volixibat work compared to current PSC treatments?

Volixibat is an IBAT inhibitor that blocks bile acid reabsorption, potentially reducing liver bile acid accumulation. Current PSC treatments mainly focus on symptom management rather than addressing underlying disease mechanisms.